Patent Issued for Multispecific antibodies against CD40 and CD137 (USPTO 12077596).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      This document is a patent for multispecific antibodies that target CD40 and CD137, proteins involved in immune responses and cancer. The patent describes the amino acid sequences of the antibodies' antigen-binding regions and their potential use in treating cancer. The antibodies have specific sequences that allow them to bind to CD40 and CD137 with high affinity. The patent also provides information on the antibodies' isotype, subclass, and specific amino acid substitutions in the heavy chains. This information may be valuable for researchers studying cancer treatment and immunotherapy. The patent is assigned to Genmab A/S. [Extracted from the article]
    • Abstract:
      Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)